🔗 Share this article

While the United States continues making sweeping adjustments to its vaccine recommendations, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by casting doubt on Covid vaccinations throughout the global health crisis and has zeroed in on potential fatalities after Covid immunization in her recent position at the FDA.

Scheduled Changes to Childhood Immunization Schedule

Agency leaders were set to announce radical revisions to the childhood immunization program in December, synchronizing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with much of the international standard with no evidence for public health gain. The announcement has been postponed until the new year.

Instead of the top vaccines chief, Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to run the center this year.

Consolidating Power at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting specific pediatric vaccine recommendations in the US in order to be more like the Danish model, a society with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – traditionally the domain of Prasad, head of the FDA’s CBER – instead of medication approval.

Concerns Over Qualifications

The appointee has no apparent experience in medication creation, oversight or administrative roles, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a large organization. She lacks background in drug approvals.”

Former commissioners of CBER would “be deeply familiar with regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that prior appointees who headed the center have had.”

CDER has an vast portfolio at the FDA, the former commissioner pointed out.

“The public just focuses on the new drug program, but the generic drug division authorizes thousands of generic medications. There’s a biologic copycat branch, over-the-counter program and more, and all of those have to be looked after,” she said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a significant management element to the position, which supervises more than 5,000 staff members. “It’s a huge leadership role, if you perform it correctly,” she said.

Official Statement and Disputed Initiatives

In response to concerns about Dr. Høeg's qualifications and whether this selection signifies more teamwork among agency officials on immunizations, a spokesperson stated that the “concerns are based on inaccurate presumptions”.

“This background matches the duties of her role,” the representative said, noting the months Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a controversial one-day therapy clearance system that reportedly troubled her predecessors. “How are these medications being picked for this expedited pathway? Who makes the decisions?” Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he remarked, “the FDA looks to be trending towards less stringent rules of pharmaceuticals, with the exception of vaccines.”

Documented Past Work on Vaccines

Regarding immunizations, Høeg has a clearer, if troubling, history, Howard said. She authored a analysis using unverified public submissions to determine the incidence of heart inflammation after Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Among her “desired changes” for the new administration included changing regulations for new vaccines and halting “unnecessary” immunizations, she remarked post-election on a audio program. At the FDA, Dr. Høeg has reportedly proposed preventing adolescent males from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who starts off with her conclusions and works backwards to retrofit the data in a very deceptive, fraudulent way,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|